Nano Ablation Biotech
Hangzhou
About Nano Ablation Biotech
Hangzhou Nano Ablation Biotech is committed to building an innovative ablation platform based on bioelectric technology. The company has developed an internationally leading next-generation pulse ablation technology, nanosecond wave ablation, which can achieve local accurate ablation, a breakthrough into the forbidden area that traditional ablation technology can not, and is expected to create a strong immune response that can address traditional tumor surgical problems of tumor recurrence and metastasis. At present, Hangzhou Nano Ablation Biotech is about to complete the world's first registered clinical trial for nanosecond wave tumor ablation. The company has a pipeline of products targeting liver cancer, pancreatic cancer, and cardiac ablation.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Funding stage: Late Stage Venture
- Last round: Series C (Feb 2025)
- Website: r-ablation.com
- Phone: 0571 - - 89055971
Industries & Categories
Biotechnology, Electronics, Medical Device
Canonical: https://fsome.com/organization/nano-ablation-biotech-3192544 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.